LN-229 In Vitro Post-translational Modifications Assay

This assay is to provide LN-229-based In Vitro Post-translational Modifications Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

LN-229

Human

The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987].

Glioblastoma

Oncology

In Vitro Post-translational Modifications Assay

LN-229-cell based In Vitro Post-translational Modifications Assay

Immunoassays and mass spectrometry techniques are considered ideal techniques for the detection of post-translational modification. Both the genetic and epigenetic modifications have contributed to the initiation and progression of cancer.

Gene and Protein Expression Assays

Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.